Study of Oligorecurrent Prostate Cancer Finds Winning Combination | MedPage Today

Radiosa trial results give hope for Oligorecurrent PC Breakthrough in Treating Oligorecurrent Prostate Cancer Adding Short-Term Hormone Therapy to Targeted Radiation Cuts Disease Progression Risk in Half A groundbreaking study from Italy has demonstrated significant benefits from combining targeted radiation with a brief course of hormone therapy for men with oligorecurrent prostate cancer. This important development could change treatment approaches for many patients in this specific situation. What is Oligorecurrent Prostate Cancer? Oligorecurrent prostate cancer refers to a state where the cancer has returned after initial treatment with a limited number of metastases (typically 1-3 spots) detected on advanced imaging scans. This pattern of recurrence represents an opportunity for targeted treatment that may delay the need for long-term systemic therapy. The RADIOSA Trial: A Game-Changing Study The phase II RADIOSA trial conducted at the European Institute of Oncology in Milan...